Usage
:Glimepiride is the third generation sulfonylurea antidiabetic drug, having the functions of inhibiting synthesis of hepatic glucose, improving insulin-stimulated glucose transport in skeletal muscle and promoting insulin seretion. This product is suitable for type 2 diabetic patient who can’t control blood glucose by diet-treated only, exercise therapy and lose weight.
*The following content is generated by AI and is for reference only.
Glimipride is a second-generation sulfonylurea antidiabetic agent widely utilized in the management of type 2 diabetes mellitus. Its chemical identity is defined by the molecular formula C₂₄H₂₅N₃O₅S and carries the CAS registry number 95316-08-4. Structurally, it features a pyridine ring substituted with a methyl group and a ureido linkage connecting to a phenylsulfonyl moiety, which is crucial for its pharmacological activity. The primary mechanism of action involves stimulating insulin secretion from pancreatic beta cells by binding to ATP-sensitive potassium channels on their cell membranes. This binding induces channel closure, leading to membrane depolarization, calcium influx, and subsequent exocytosis of insulin granules. Unlike first-generation agents, glimepiride possesses a rapid onset of action and a relatively short duration, allowing for flexible once-daily dosing regimens that improve patient adherence. It is indicated as an adjunct to diet and exercise for glycemic control in patients whose hyperglycemia cannot be managed by lifestyle modifications alone or when metformin monotherapy is insufficient or contraindicated. Clinically, glimepiride is available in tablet formulations ranging from 1 mg to 4 mg, facilitating dose titration based on individual patient response and renal function. While generally well-tolerated, the most significant adverse effect is hypoglycemia, particularly in elderly patients or those with irregular meal patterns. Other potential side effects include weight gain, gastrointestinal disturbances, and rare hypersensitivity reactions. As a potent oral hypoglycemic, glimepiride remains a cornerstone therapy in global diabetes care guidelines, offering effective blood glucose reduction with a favorable safety profile when used appropriately under medical supervision. Its widespread availability and established efficacy make it a standard choice for clinicians managing non-insulin-dependent diabetes across diverse healthcare settings worldwide.